a Department of Hematology , University Hospital of Salamanca-IBSAL , Salamanca , Spain.
b Department of Hematology, University Hospital of Porto-UMIB/ICBAS/UP , Porto , Portugal.
Ann Med. 2019 Mar;51(2):141-148. doi: 10.1080/07853890.2019.1587498. Epub 2019 Apr 16.
Hermansky-Pudlak syndrome (HPS) is a rare inherited platelet disorder characterized by bleeding diathesis, oculocutaneous albinism (OCA) and a myriad of often-serious clinical complications. We established the clinical and laboratory phenotype and genotype of six unrelated pedigrees comprising ten patients with clinical suspicion of HPS; including platelet aggregation, flow cytometry, platelet dense granule content, electron microscopy and high-throughput sequencing (HTS). The clinical presentation showed significant heterogeneity and no clear phenotype-genotype correlations. HTS revealed two known and three novel disease-causing variants. The Spanish patients carried a homozygous p.Pro685Leufs17* deletion ( = 2) in , or the novel p.Arg822* homozygous variant ( = 1) in . In the case of two Turkish sisters, a novel missense homozygous variant (p.Leu91Pro) was found. In two Portuguese families, genetic studies confirmed a previously reported nonsense variant (p.Gln103*) in in three patients and a novel duplication (p.Leu22Argfs*33) in in two unrelated patients. Our findings expand the mutational spectrum of HPS, which may help in investigating phenotype-genotype relationships and assist genetic counselling for affected individuals. This approach is a proof of principle that HTS can be considered and used in the first-line diagnosis of patients with biological and clinical manifestations suggestive of HPS. Key messages We established the relationships between the clinical and laboratory phenotype and genotype of six unrelated pedigrees comprising ten patients with clinical suspicion of HPS. Molecular analysis is useful in confirming the diagnosis and may offer some prognostic information that will aid in optimizing monitoring and surveillance for early detection of end-organ damage. This approach is a proof of principle that HTS can be considered and used in the first-line diagnosis of patients with biological and clinical manifestations suggestive of HPS.
Hermansky-Pudlak 综合征(HPS)是一种罕见的遗传性血小板疾病,其特征为出血倾向、眼皮肤白化病(OCA)和多种常伴有严重临床并发症。我们建立了六个不相关家系共 10 例临床疑诊 HPS 患者的临床和实验室表型及基因型;包括血小板聚集、流式细胞术、血小板致密颗粒含量、电子显微镜和高通量测序(HTS)。临床表现具有显著异质性,且无明确的表型-基因型相关性。HTS 发现了两个已知和三个新的致病变异。西班牙患者携带 中的纯合 p.Pro685Leufs17缺失(=2)或 中的新型 p.Arg822纯合变异(=1)。对于两位土耳其姐妹,发现了一种新型错义纯合变异(p.Leu91Pro)。在两个葡萄牙家族中,遗传研究证实了先前报道的三个患者中 中的无义变异(p.Gln103*)和两个不相关患者中 中的新重复(p.Leu22Argfs*33)。我们的发现扩展了 HPS 的突变谱,这有助于研究表型-基因型的关系,并为受影响个体的遗传咨询提供帮助。这种方法证明了 HTS 可以作为疑似 HPS 患者的一线诊断,具有原理验证意义。关键信息我们建立了六个不相关家系共 10 例临床疑诊 HPS 患者的临床和实验室表型及基因型之间的关系。分子分析有助于确诊,并可能提供一些预后信息,以帮助优化监测和随访,以早期发现终末器官损伤。这种方法证明了 HTS 可以作为疑似 HPS 患者的一线诊断,具有原理验证意义。